Aardvark Therapeutics, Inc. (AARD) Price & Analysis

Compare

86 Followers

AARD Stock Chart & Stats

$9.37

Market closed

$9.37

Day’s Range― - ―

52-Week Range$4.88 - $19.58

Previous CloseN/A

VolumeN/A

Average Volume (3M)166.37K

Market Cap

$206.85M

Enterprise Value$163.19M

Total Cash (Recent Filing)$126.35M

Total Debt (Recent Filing)$545.00K

Price to Earnings (P/E)―

Beta1.35

Next Earnings

Apr 06, 2026

EPS Estimate

-0.83

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.75

Shares Outstanding21,773,272

10 Day Avg. Volume148,283

30 Day Avg. Volume166,372

Financial Highlights & Ratios

PEG Ratio-0.05

Price to Book (P/B)-3.38

Price to Sales (P/S)0.00

P/FCF Ratio-10.15

Enterprise Value/Market Cap0.79

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-16.32K

Enterprise Value/Ebitda-3.14

Forecast

1Y Price Target

$30.63

Price Target Upside226.89% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)-2.97

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial PositionThe company has a strong financial position with $126.4M in cash, providing a runway into 2027, which supports its growth and operational capabilities.

Market OpportunityThe PWS market is large, and even capturing a minority share presents a meaningful opportunity for ARD-101.

Therapeutic DevelopmentARD-101 has shown promising results in a phase 2 clinical trial, demonstrating potential effectiveness in addressing hunger-driven symptoms of Prader-Willi Syndrome.

Bears Say

Clinical Data ChallengesBoth the clinical data and the mechanism/biology behind ARD-101 are considered imperfect and present real risk.

Trial RiskDespite optimism, there is a risk that the trial could fail simply by chance due to the challenging nature of Prader-Willi Syndrome.

Aardvark Therapeutics, Inc. News

Aardvark Therapeutics reports Q3 EPS (75c), consensus (80c)

In October 2025, Aardvark reached alignment with the FDA on a protocol amendment to change the minimum age...

13d ago

AARD

Aardvark Thera sees cash, equivalents sufficient to fund operations into 2027

16:24 EST Aardvark Thera sees cash, equivalents sufficient to fund operations into 2027 Published first on TheFly –...

13d ago

AARD

Datadog, Trade Desk upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

19d ago

Aardvark Therapeutics initiated with a Buy at BTIG

BTIG initiated coverage of Aardvark Therapeutics (AARD) with a Buy rating and $26 price target Aardvark is a...

19d ago

AARD

Aardvark Therapeutics presents data on metabolic obesity pipeline programs

Aardvark Therapeutics (AARD) presented data at the ObesityWeek 2025 conference demonstrating the mechanistic rationale and therapeutic potential of...

22d ago

AARD

Aardvark Therapeutics Reports Q3 2025 Financial Results

Aardvark Therapeutics, Inc. ( ($AARD) ) has released its Q3 earnings. Here is a breakdown of the information...

8d ago

AARD

Aardvark Therapeutics, Inc.: Undervalued Potential in the Obesity Treatment Market with Promising Pipeline

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Aardvark Therapeutics, Inc., retaining the price target...

16d ago

AARD

Aardvark Therapeutics Hosts Investor Webinar on Drug Programs

Aardvark Therapeutics, Inc. ( ($AARD) ) has issued an update. On November 5, 2025, Aardvark Therapeutics, Inc. held...

20d ago

AARD

Promising Potential of Aardvark Therapeutics: Buy Rating Based on ARD-201 and ARD-101 Developments

Michael Ulz, an analyst from Morgan Stanley, maintained the Buy rating on Aardvark Therapeutics, Inc.. The associated price...

21d ago

AARD

Aardvark Therapeutics Showcases Obesity Research at ObesityWeek

Aardvark Therapeutics, Inc. ( ($AARD) ) has issued an announcement. On November 4, 2025, Aardvark Therapeutics presented research...

22d ago

AARD

Aardvark Therapeutics Advances PWS Treatment with ARD-101 Study

Aardvark Therapeutics, Inc. (($AARD)) announced an update on their ongoing clinical study. Study Overview: Aardvark Therapeutics, Inc. is...

30d ago

AARD

Aardvark Therapeutics’ ARD-101 Study: A New Hope for Prader-Willi Syndrome

Aardvark Therapeutics, Inc. (($AARD)) announced an update on their ongoing clinical study. Study Overview: The Hunger Elimination or...

30d ago

AARD

Aardvark Therapeutics Aligns with FDA on Trial Amendment

Aardvark Therapeutics, Inc. ( ($AARD) ) has shared an announcement. On October 8, 2025, Aardvark Therapeutics announced an...

2M ago

AARD

Aardvark Therapeutics announces FDA alignment on HERO trial protocol amendment

Aardvark Therapeutics (AARD) announces alignment with the U.S. Food and Drug Administration on a protocol amendment to the...

2M ago

AARD

AARD FAQ

What was Aardvark Therapeutics, Inc.’s price range in the past 12 months?

Aardvark Therapeutics, Inc. lowest stock price was $4.88 and its highest was $19.58 in the past 12 months.

What is Aardvark Therapeutics, Inc.’s market cap?

Aardvark Therapeutics, Inc.’s market cap is $206.85M.

When is Aardvark Therapeutics, Inc.’s upcoming earnings report date?

Aardvark Therapeutics, Inc.’s upcoming earnings report date is Apr 06, 2026 which is in 131 days.

How were Aardvark Therapeutics, Inc.’s earnings last quarter?

Aardvark Therapeutics, Inc. released its earnings results on Nov 13, 2025. The company reported -$0.75 earnings per share for the quarter, beating the consensus estimate of -$0.799 by $0.049.

Is Aardvark Therapeutics, Inc. overvalued?

According to Wall Street analysts Aardvark Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aardvark Therapeutics, Inc. pay dividends?

Aardvark Therapeutics, Inc. does not currently pay dividends.

What is Aardvark Therapeutics, Inc.’s EPS estimate?

Aardvark Therapeutics, Inc.’s EPS estimate is -0.83.

How many shares outstanding does Aardvark Therapeutics, Inc. have?

Aardvark Therapeutics, Inc. has 21,773,272 shares outstanding.

What happened to Aardvark Therapeutics, Inc.’s price movement after its last earnings report?

Aardvark Therapeutics, Inc. reported an EPS of -$0.75 in its last earnings report, beating expectations of -$0.799. Following the earnings report the stock price went down -8.656%.

Which hedge fund is a major shareholder of Aardvark Therapeutics, Inc.?

Currently, no hedge funds are holding shares in AARD

Aardvark Therapeutics, Inc. Stock Smart Score

Outperform

Fundamentals

Return on Equity

-48.06%

Trailing 12-Months

Asset Growth

59.10%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Aardvark Therapeutics, Inc.

Aardvark Therapeutics, Inc. (AARD) is a biotechnology company focused on developing innovative therapies for metabolic and inflammatory diseases. The company specializes in creating and advancing novel treatments aimed at addressing unmet medical needs in these sectors. Its core products include proprietary drug candidates designed to modulate metabolic pathways and reduce inflammation, ultimately improving patient outcomes and quality of life.

Aardvark Therapeutics, Inc. (AARD) Earnings & Revenues

Historic Earnings Reports

AARD Stock 12 Month Forecast

Average Price Target

$30.63

▲(226.89% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","18":"$18","29":"$29","40":"$40","51":"$51"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.63,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$30.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,18,29,40,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.69,13.713846153846154,16.737692307692306,19.76153846153846,22.785384615384615,25.80923076923077,28.833076923076923,31.856923076923074,34.88076923076923,37.90461538461538,40.92846153846154,43.95230769230769,46.97615384615384,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.69,12.223846153846154,13.757692307692306,15.29153846153846,16.825384615384614,18.35923076923077,19.89307692307692,21.426923076923075,22.96076923076923,24.494615384615383,26.028461538461535,27.56230769230769,29.09615384615384,{"y":30.63,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.69,11.252307692307692,11.814615384615385,12.376923076923077,12.939230769230768,13.501538461538463,14.063846153846153,14.626153846153846,15.188461538461539,15.750769230769231,16.313076923076924,16.875384615384615,17.43769230769231,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.3,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.3,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.3,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.3,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12.73,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12.73,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.29,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.33,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.13,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.56,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.13,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.86,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.69,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >